高级检索
当前位置: 首页 > 详情页

Chinese management guidelines for radioactive iodine-refractory differentiated thyroid cancer (2025 edition)

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China [2]Department of Nuclear Medicine, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, China [3]Department of Nuclear Medicine, West China Hospital of Sichuan University, Chengdu, Sichuan, China [4]Department of Nuclear Medicine, China-Japan Union Hospital, Jilin University, Changchun, Jilin, China [5]Department of Nuclear Medicine, Hubei Province Key Laboratory of Molecular Imaging, Union Hospital, Tongji Medical College, Huazhong University Science and Technology, Wuhan, Hubei, China [6]Department of Nuclear Medicine, Shanghai Sixth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China [7]Department of Oncology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China [8]Department of Radiotherapy, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China [9]Department of Oncology, Peking University International Hospital, Beijing, China [10]Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China [11]Department of Nuclear Medicine, The First Hospital of Jilin University, Changchun, Jilin, China [12]Department of Pathology, Shanghai Sixth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China [13]Department of Radiotherapy, Qingdao Municipal Hospital, Qingdao, Shandong, China [14]Department of Nuclear Medicine, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China [15]Department of Head and Neck Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China [16]Department of Endocrinology, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital, Hangzhou Medical College), Hangzhou, Zhejiang, China [17]Endocrine and Diabetes Center, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, Jiangsu, China [18]Department of Nuclear Medicine, the First Affiliated Hospital, Xi’an Jiaotong University, Xi’an, Shaanxi, China [19]National Center for Respiratory Medicine. State Key Laboratory of Respiratory Health and Multimorbidity. National Clinical Research Center for Respiratory Diseases. Institute of Respiratory Medicine, Chinese Academy of Medical Sciences. Department of Ultrasound, Center of Respiratory Medicine, China-Japan Friendship Hospital, Beijing, China [20]Institute of Clinical Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
出处:
ISSN:

关键词: Radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC) Guideline Committee Chinese Society of Clinical Oncology (CSCO) Chinese Society of Nuclear Medicine (CSNM) Thyroid oncology committee of China Anti-Cancer Association (CACA)

摘要:
Radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC) has become a challenge in clinical practice, particularly in China with a high incidence and undesirable survival outcome. Since the publication of first China consensus on the diagnosis and treatment of RAIR-DTC in 2019, significant and rapid advances have occurred in the field both in China and internationally. This guideline aims to inform Chinese clinicians, researchers, patients, and health policy makers on the latest evidence and recommendations, to further standardize the clinical diagnosis and treatment of RAIR-DTC.The structured clinical questions addressed in this guideline were derived from clinical diagnostic and treatment processes, with references to study, prior guidelines, expert consensus, and systematic reviews, etc. The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) was used for quantitative and qualitative evaluation of the evidence. The editorial process was completely independent of the guideline development group.The guideline addressed 26 clinical questions and formed 35 recommendations. In this guideline, the definition criteria for RAIR-DTC was optimized, prediction and identification was based on evidence including molecular testing, dynamic biochemical changes, and multimodal imaging. Comprehensive pre-treatment clinical evaluation was emphasized and tailored for individualized decision-making. The combination of systematic therapy and surgery, and the redifferentiation followed by RAI therapy were also reviewed and updated. Molecular imaging plays a unique role in the pre-assessing and therapeutic response evaluation for RAIR-DTC.We have updated and developed evidence-based recommendations with the aim of providing scientific, rigorous, and comprehensive guidance for the clinical diagnosis and treatment of RAIR-DTC patients in China. We hope to share our guideline with colleagues out of China, with the expectation of further comments and suggestions.© 2025. The Author(s).

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2025]版:
大类 | 1 区 医学
小类 | 1 区 核医学
最新[2025]版:
大类 | 1 区 医学
小类 | 1 区 核医学
JCR分区:
出版当年[2024]版:
Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
最新[2024]版:
Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

影响因子: 最新[2024版] 最新五年平均 出版当年[2024版] 出版当年五年平均 出版前一年[2024版]

第一作者:
第一作者机构: [1]Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:59653 今日访问量:0 总访问量:4873 更新日期:2025-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号